Stocks making the biggest moves premarket: Oracle, Novo Nordisk, Hims & Hers Health, Kroger
Check out the companies making headlines before the bell. Oracle — Shares rose 2% after the technology firm received an
Read More
Novo Nordisk A/S
Novo Nordisk sues Hims & Hers over copycat versions of Wegovy drugs; Hims stock falls 18%
Novo Nordisk on Monday said it is suing online telehealth provider Hims & Hers for mass marketing cheaper, unapproved copies
Read More
FDA says Novo Nordisk’s TV ad for obesity pill includes ‘false or misleading’ claims
The Food and Drug Administration said Novo Nordisk’s TV advertisement for its newly launched Wegovy pill for obesity included “false
Read More
Stocks making the biggest moves midday: Amazon, Centene, Roblox and more
Check out the companies making headlines in midday trading. Centene — Shares of the health insurance provider slid 5%. Guidance
Read More
Stocks making the biggest moves premarket: Amazon, Reddit, Strategy, Molina, Strategy, Eli
These are the stocks posting the largest moves in premarket trading. This article was originally published by a Cnbc.com. Read
Read More
Stocks making the biggest moves midday: Novo Nordisk, Palantir, AES, Rocket and more
Check out the companies making headlines before the bell: Novo Nordisk — The maker of obesity drug Wegovy’s U.S. stock
Read More
We’re raising our price target on Eli Lilly as the GLP-1 leader delivers a huge beat
Eli Lilly ‘s fourth-quarter results blew past Wall Street estimates on Wednesday, as key GLP-1 drugs, Mounjaro for diabetes and
Read More
Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial
Smith Collection | Archive Photos | Getty Images Pfizer on Tuesday said its experimental obesity drug, which it acquired through
Read More
Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro
Eli Lilly on Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its
Read More
Novo Nordisk shares tumble 18% as CEO warns it will get worse before it gets better
Just as Novo Nordisk showed signs of a recovery, another cold shower hit investors as the drugmaker surprise pre-released its
Read More